Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms

References

• GOLD. 2019 global strategy for prevention, diagnosis and management of COPD. Available from: https://goldcopd.org/gold-reports/(Accessed 1211, 2018). Fontana, WI, USA: Global Initiative for Chronic Obstructive Lung Disease, Inc., 2019
   Google Scholar
• Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:71–86. doi:10.1016/j.ccm.2013.10.00424507838
   PubMed Web of Science ®Google Scholar
• Cataldo D, Derom E, Liistro G, et al. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. Int J Chron Obstruct Pulmon Dis. 2018;13:2089–2099. doi:10.2147/COPD.S16425930013336
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; 9: CD006829.22972099
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332–338. doi:10.1164/rccm.200712-1869OC18511702
   PubMed Web of Science ®Google Scholar
• Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting beta-agonists and inhaled corticosteroids compared with long-acting beta-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014;312:1114–1121. doi:10.1001/jama.2014.1143225226477
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee YK, Kim EK, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med. 2010;104:542–549. doi:10.1016/j.rmed.2009.10.02419926461
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410–419. doi:10.1183/13993003.01359-201526828055
   PubMed Web of Science ®Google Scholar
• Dicker AJ, Crichton ML, Pumphrey EG, et al. Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141:117–127. doi:10.1016/j.jaci.2017.04.02228506850
   PubMed Web of Science ®Google Scholar
• Contoli M, Pauletti A, Rossi MR, et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50:1700451. doi:10.1183/13993003.00711-201728982774
   PubMed Web of Science ®Google Scholar
• Chalmers JD. POINT: should an attempt be made to withdraw inhaled corticosteroids in all patients with stable GOLD 3 (30%</= FEV1<50% predicted) COPD? Yes. Chest. 2018;153:778–782. doi:10.1016/j.chest.2018.01.02929474807
   PubMed Web of Science ®Google Scholar
• Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:295–304. doi:10.2147/COPD.S4236623836970
   PubMed Web of Science ®Google Scholar
• Arkhipov V, Arkhipova D, Miravitlles M, Lazarev A, Stukalina E. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chron Obstruct Pulmon Dis. 2017;12:3255–3262. doi:10.2147/COPD.S14299729138554
   PubMed Web of Science ®Google Scholar
• Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22:92–100. doi:10.4104/pcrj.2012.0009223135217
   PubMedGoogle Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease. N Engl J Med. 1999;340:1948–1953. doi:10.1056/NEJM19990624340250310379018
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Bmj. 2000;320:1297–1303. doi:10.1136/bmj.320.7245.129710807619
   PubMed Web of Science ®Google Scholar
• Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003;21:68–73.12570111
   PubMed Web of Science ®Google Scholar
• Zervas E, Samitas K, Gaga M, Beghe B, Fabbri LM. Inhaled corticosteroids in COPD: pros and cons. Curr Drug Targets. 2013;14:192–224.23256718
   PubMed Web of Science ®Google Scholar
• Cheng SL, Su KC, Wang HC, Perng DW, Yang PC. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. Drug Des Devel Ther. 2014;8:601–607. doi:10.2147/DDDT.S63100
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–1826. doi:10.1016/S0140-6736(16)30069-127203508
   PubMed Web of Science ®Google Scholar
• Rossi A, van der Molen T, Del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44:1548–1556. doi:10.1183/09031936.0012681425359348
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81.12570112
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912–919.14680078
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest. 2009;136:1029–1038. doi:10.1378/chest.09-082119633090
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26. doi:10.1164/rccm.200707-973OC17916806
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131:636–645. doi:10.1016/j.jaci.2012.12.156423360759
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435–442. doi:10.1016/S2213-2600(15)00106-X25878028
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:523–525. doi:10.1164/rccm.201502-0235LE26051430
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• Roche N, Chapman KR, Vogelmeier CF, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. data from the FLAME trial. Am J Respir Crit Care Med. 2017;195:1189–1197. doi:10.1164/rccm.201701-0193OC28278391
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45:525–537. doi:10.1183/09031936.0012891425537556
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; 3: CD010115.24615270
   PubMed Web of Science ®Google Scholar
• Brode SK, Campitelli MA, Kwong JC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J. 2017;50:1700037. doi:10.1183/13993003.00711-201728931659
   PubMed Web of Science ®Google Scholar
• Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66:699–708. doi:10.1136/thx.2011.16002821602540
   PubMed Web of Science ®Google Scholar
• Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123:1001–1006. doi:10.1016/j.amjmed.2010.06.01920870201
   PubMed Web of Science ®Google Scholar
• Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2:CD012066.28185242
   PubMed Web of Science ®Google Scholar
• EMA. Inhaled Corticosteroids Containing Medicinal Products Indicated in the Treatment of Chronic Obstructive Pulmonary Disease. London, UK: European Medicines Agency; 2016.
   Google Scholar
• EMA. PRAC Reviews Known Risk of Pneumonia with Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease. London, UK: European Medicines Agency; 2016.
   Google Scholar
• Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; 2: CD002991.22786484
   PubMed Web of Science ®Google Scholar
• Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009;14:983–990. doi:10.1111/j.1440-1843.2009.01589.x19740259
   PubMed Web of Science ®Google Scholar
• Uboweja A, Malhotra S, Pandhi P. Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis. Fundam Clin Pharmacol. 2006;20:305–309. doi:10.1111/j.1472-8206.2006.00397.x16671966
   PubMed Web of Science ®Google Scholar
• Huang KW, Kuan YC, Chi NF, Huang YH, Luo JC, Chien LN. Chronic obstructive pulmonary disease is associated with increased recurrent peptic ulcer bleeding risk. Eur J Intern Med. 2017;37:75–82. doi:10.1016/j.ejim.2016.09.02027727075
   PubMed Web of Science ®Google Scholar
• Rossi AP, Zanardi E, Zamboni M, Rossi A. Optimizing treatment of elderly COPD patients: what role for inhaled corticosteroids? Drugs Aging. 2015;32:679–687. doi:10.1007/s40266-015-0291-826297533
   PubMed Web of Science ®Google Scholar
• van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166:1358–1363. doi:10.1164/rccm.200206-512OC12406823
   PubMed Web of Science ®Google Scholar
• Choudhury AB, Dawson CM, Kilvington HE, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res. 2007;8:93. doi:10.1186/1465-9921-8-9118162137
   PubMed Web of Science ®Google Scholar
• Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60:480–487. doi:10.1136/thx.2004.03428015923248
   PubMed Web of Science ®Google Scholar
• Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15:77. doi:10.1186/1465-9921-15-7725005873
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Worth H, Buhl R, et al. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis. 2017;12:487–494. doi:10.2147/COPD.S12561628203072
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–1294. doi:10.1056/NEJMoa140715425196117
   PubMed Web of Science ®Google Scholar
• Magnussen H, Tetzlaff K, Bateman ED, et al. Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. Eur Respir J. 2016;47:651–654. doi:10.1183/13993003.01644-201526585433
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390–398. doi:10.1016/S2213-2600(16)00100-427066739
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Gaga M, Aalamian-Mattheis M, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res. 2017;18:140. doi:10.1186/s12931-017-0622-x28720132
   PubMed Web of Science ®Google Scholar
• Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198:329–339. doi:10.1164/rccm.201803-0405OC29779416
   PubMed Web of Science ®Google Scholar
• Frith PA, Ashmawi S, Krishnamurthy S, et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology. 2018;23:1152–1159. doi:10.1111/resp.1337430074294
   PubMed Web of Science ®Google Scholar
• Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest. 2015;148:1177–1183. doi:10.1378/chest.15-062726110239
   PubMed Web of Science ®Google Scholar
• Kaplan AG. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int J COPD. 2015;10:2535–2548. doi:10.2147/COPD.S93321
   Google Scholar
• Ferreira AJ, Reis A, Marçal N, Pinto P, Bárbara C. COPD A stepwise or a hit hard approach? Rev Port Pneumol. 2016;22:214–221.26935750
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Cosio BG, Arnedillo A, et al. A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respir Res. 2017;18:198. doi:10.1186/s12931-017-0682-y29183382
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Alvarez-Gutierrez FJ, Calle M, et al. Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. Eur Respir J. 2017;49:1700068. doi:10.1183/13993003.00068-201728461301
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Bobak A, Scullion J, Murphy A. Withdrawal of ICS treatment in primary care: a practical guide. Pract Nurs. 2017;28:22–27. doi:10.12968/pnur.2017.28.1.22
   Google Scholar
• Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE study group. Respir Med. 1999;93:161–166.10464871
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:1333–1343. doi:10.1164/rccm.201604-0733OC27409253
   PubMed Web of Science ®Google Scholar
• Kardos P, Vogelmeier C, Worth H, et al. A two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: the DACCORD observational study. Respir Med. 2017;124:57–64. doi:10.1016/j.rmed.2017.02.00728284322
   PubMed Web of Science ®Google Scholar
• Harlander M, Barrecheguren M, Turel M, Miravitlles M. Should patients switched from D to B in the GOLD 2017 classification be discontinued from inhaled corticosteroids? COPD. 2017;14:465–468. doi:10.1080/15412555.2017.134223328745524
   PubMedGoogle Scholar
• Avdeev SN, Aisanov ZR, Belevskii AS, et al. Prospects for pharmacotherapy of chronic obstructive pulmonary disease: capabilities of combined bronchodilator drugs and the place of inhalation corticosteroids. Expert panel report [Article in Russian]. Pulmonologiya. 2016;26:65–72. doi:10.18093/0869-0189-2016-26-1-65-72
   Google Scholar
• Avdeev SN, Aisanov ZR, Belevskii AS, et al. New options for prevention of exacerbations of chronic obstructive pulmonary disease. Report of the expert group of the Russian respiratory society [Article in Russian]. Pulmonologiya. 2017;27:108–113. doi:10.18093/0869-0189-2017-27-1-108-113
   Google Scholar
• Avdeev SN, Belevskii AS, Aisanov ZR, et al. Capabilities of inhalation therapy for prevention of exacerbations of chronic obstructive pulmonary disease. Report of the expert panel of the Russian respiratory society [Article in Russian]. Pulmonologiya. 2018;28:368–380. doi:10.18093/0869-0189-2018-28-3-368-380
   Google Scholar
• Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Amer Thorac Soc. 2015;12:27–34. doi:10.1513/AnnalsATS.201409-413OC25490706
   PubMed Web of Science ®Google Scholar
• Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD Is There an Infective Phenotype?. Respir Med. 2013;107:10–22.23218452
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Anzueto A. Antibiotic prophylaxis in COPD: why, when, and for whom? Pulm Pharmacol Ther. 2015;32:119–123. doi:10.1016/j.pupt.2014.05.00224825753
   PubMed Web of Science ®Google Scholar
• Izquierdo JL, Cosio BG. The dose of inhaled corticosteroids in patients with COPD: when less is better. Int J Chron Obstruct Pulmon Dis. 2018;13:3539–3547. doi:10.2147/COPD.S17504730498343
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–1036. doi:10.1136/thoraxjnl-2012-20287224130228
   PubMed Web of Science ®Google Scholar
• Lipworth B, Kuo CRW, Jabbal S. Current appraisal of single inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3003–3009. doi:10.2147/COPD.S17733330319248
   PubMed Web of Science ®Google Scholar
• Janson C, Stratelis G, Miller-Larsson A, Harrison TW, Larsson K. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int J Chron Obstruct Pulmon Dis. 2017;19(12):3055–3064. doi:10.2147/COPD.S143656
   Web of Science ®Google Scholar